You are here

Article Text

Article menu
Download PDFPDF
Letter
A single course of rituximab does not abrogate anti-infliximab antibodies in patients with rheumatoid arthritis
  1. B J F van den Bemt1,
  2. K Vos2,5,
  3. A A den Broeder3,
  4. M Blom4,
  5. R M Thurlings2,
  6. G M Bartelds5,
  7. S O Stapel6,
  8. P Barrera4,
  9. P P Tak2,
  10. M T Nurmohamed5,
  11. G-J Wolbink6
  1. 1
    Department of Pharmacy, Sint Maartenskliniek, Nijmegen, The Netherlands
  2. 2
    Division of Clinical Immunology and Rheumatology, Academic Medical, Center/University of Amsterdam, Amsterdam, The Netherlands
  3. 3
    Department of Rheumatology, Sint Maartenskliniek, Nijmegen, The Netherlands
  4. 4
    Department of Rheumatology, University Medical Center Nijmegen, Nijmegen, The Netherlands
  5. 5
    Department of Rheumatology, Jan van Breemen Institute, Amsterdam, The Netherlands
  6. 6
    Department of Immunopathology, Sanquin Research, Amsterdam, The Netherlands
  1. B J F van den Bemt, Sint Maartenskliniek, department of Pharmacy, PO Box 9011, 6500 GM, Nijmegen, The Netherlands; b.vandenbemt{at}maartenskliniek.nl

https://doi.org/10.1136/ard.2008.095448

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    The development of anti-infliximab antibodies in 8% to 43% of infliximab-treated patients is associated with decreased efficiency and increased risk of adverse effects.1–3 An intervention that can diminish anti-infliximab antibody formation is therefore warranted. Rituximab, a chimeric monoclonal antibody that selectively depletes CD20-positive B lymphocytes, could potentially inhibit the human antibody response against infliximab. Therefore, we assessed the proportion of patients with rheumatoid arthritis (RA) in which treatment with rituximab resulted in the depletion of anti-infliximab antibodies.

    Consecutive patients with RA with detectable anti-infliximab antibodies, who were initiated on treatment with either rituximab or adalimumab, were included in this prospective controlled cohort study. …

    View Full Text

    Footnotes

    • Competing interests: None declared.